Usefulness of inhaled magnesium sulfate in the coadjuvant management of severe asthma crisis in an emergency department
Introduction
Asthma is an important public health chronic respiratory illness due to its frequency, altered quality of life, and significant health costs along with the impact of severe asthma being able to trigger prolonged hospitalizations and death. Of the total asthma expenditure in the U.S., 25% is attributed to emergency care [1]. Standard treatment for asthma crisis includes short-acting bronchodilator (SAB), β2-agonists and inhaled anticholinergics and corticosteroids, in addition to general management. Intravenous magnesium sulfate (MgSO4) may be added in severe crisis unresponsive to standard treatment [2] but requires special monitoring [3]. MgSO4 produces smooth muscle relaxation, blocking acetylcholine and histamine release, and a reduction in the neutrophil burst [4], leading to improved pulmonary mechanics [5], [6]. Inhaled MgSO4 use is controversial. Studies addressing this subject differ methodologically and are heterogeneous, non-comparable, and with different therapeutic interventions and primary outcomes. Nevertheless, the Global Initiative in National Asthma (GINA) recommendations supported by meta-analysis [7], [8] approve its use during a crisis [2].
The objective of this study was to evaluate the usefulness of inhaled MgSO4 as an adjuvant to the standard treatment (compared with placebo), on spirometry and pulse oximetry in severe asthmatic crisis and to determine whether this effect decreases hospital admissions.
Section snippets
Material and methods
We conducted a randomized, placebo-controlled, double-blind trial to assess the efficacy of standard management adding inhaled MgSO4 compared with the standard treatment plus placebo in patients with severe acute asthma at the National Institute of Respiratory Diseases (INER), a tertiary-care teaching-hospital and national referral center in Mexico City for respiratory disorders. The INER takes care of 1500 patients in asthmatic crisis each year, 2% of whom warrant hospitalization [9]. The
Results
All spirometry tests fulfilled the quality criteria according to ATS–ERS guidelines and were highly reproducible in FEV1, both pre-BD (0.07 ± 0.06 ml) as well as post-BD (0.08 ± 0.07 ml). The study profile is shown in Fig. 2. There were 122 eligible patients, 10 of whom did not wish to participate in the study, and 30 (TG) and 22 (CG) patients had at least one of the exclusion criteria (Fig. 2), leaving 30 patients per group for the final analysis.
In all 60 patients, normal spirometry and normal
Discussion
The study shows that adding inhaled MgSO4 to the standard treatment for severe asthma crisis with a significant impact on quality of life produces a greater improvement in symptoms and lung function determined by post-BD FEV1%p as well as oxygenation (SpO2). Treatment also reduced the risk of emergency hospitalization in a group of patients with severe asthma crisis. Additional treatments for severe asthma crisis are always helpful and MgSO4 may be one of them. GINA recommends its use as
Conclusions
This study suggests that nebulized albuterol and ipratropium bromide diluted with MgSO4 solution improves lung function and oxygen saturation and reduces the rate of ED admissions compared to the standard dilution with isotonic saline.
Acknowledgments
We appreciate the support of Sharon Morey (Scientific Communications) in the translation of the manuscript.
References (26)
- et al.
Dietary magnesium, lung function, wheezing and airway hyperreactivity in a random adult population sample
Lancet
(1994) - et al.
Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study
Lancet
(2005) - et al.
Rapid improvement of peak flow in asthmatic patients treated with parenteral methylprednisolone in the emergency department: a randomized controlled study
Ann Emerg Med
(1999) - et al.
Early parenteral corticosteroid administration in acute asthma
Am J Emerg Med
(1997) - et al.
Magnesium sulfate as a vehicle for nebulized salbutamol in acute asthma
Am J Med
(2000) - et al.
Double-blind trial of steroid tapering in acute asthma
Lancet
(1993) - et al.
Aerosolized magnesium sulfate for acute asthma. A systematic review
Chest
(2005) - et al.
A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild to moderate asthma exacerbations in adults
Ann Emerg Med
(2002) - et al.
A randomized clinical trial of magnesium sulphate as a vehicle for nebulized salbutamol in the treatment of moderate to severe asthma attacks
Pulm Pharmacol Ther
(2005) - et al.
Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: a randomized placebo-controlled trial
Lancet
(2003)